Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
Merck
AstraZeneca
Dow

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR COPIKTRA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Copiktra

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03961672 ↗ Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting National Cancer Institute (NCI) Phase 2 2020-05-13 This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
NCT03961672 ↗ Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting City of Hope Medical Center Phase 2 2020-05-13 This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
NCT03961672 ↗ Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting OHSU Knight Cancer Institute Phase 2 2020-05-13 This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
NCT04193293 ↗ A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer Suspended SecuraBio Phase 1/Phase 2 2020-02-25 This study will assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Copiktra

Condition Name

Condition Name for Copiktra
Intervention Trials
COVID-19 2
Refractory Splenic Marginal Zone Lymphoma 1
Head and Neck Squamous Cell Carcinoma 1
Recurrent Nodal Marginal Zone Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Copiktra
Intervention Trials
Lymphoma 6
Lymphoma, B-Cell 2
Lymphoma, Follicular 2
COVID-19 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Copiktra

Trials by Country

Trials by Country for Copiktra
Location Trials
United States 15
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Copiktra
Location Trials
Missouri 3
Pennsylvania 3
Massachusetts 2
Georgia 2
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Copiktra

Clinical Trial Phase

Clinical Trial Phase for Copiktra
Clinical Trial Phase Trials
Phase 2 5
Phase 1/Phase 2 2
Phase 1 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Copiktra
Clinical Trial Phase Trials
Recruiting 9
Not yet recruiting 1
Suspended 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Copiktra

Sponsor Name

Sponsor Name for Copiktra
Sponsor Trials
Verastem, Inc. 5
National Cancer Institute (NCI) 3
Secura Bio, Inc. 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Copiktra
Sponsor Trials
Industry 13
Other 11
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Johnson and Johnson
McKinsey
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.